CGEM — Cullinan Oncology Share Price
- $714.03m
- $247.15m
- 30
- 27
- 93
- 48
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.57 | ||
Price to Tang. Book | 1.57 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -41.9% | ||
Return on Equity | -30.98% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | 18.94 | n/a | n/a | 1.55 | 14.93 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Cullinan Oncology, Inc. is a biopharmaceutical company. The Company is focused on creating standards of care for patients with cancer. The Company’s lead candidate, unpartnered program, CLN-619, is a monoclonal antibody designed to stabilize expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by both cytotoxic innate and adaptive immune cells. The Company is evaluating CLN-978, is a CD19xCD3 T cell engager with extended serum half-life and, based on preclinical data, robust potency against target cells expressing low levels of CD19. The Company's Zipalertinib (CLN-081/TAS6417), is an orally available small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 (EGFRex20) insertion mutations with relative sparing of cells expressing wild-type EGFR. The Company’s other product candidates include CLN-049, CLN-418, and CLN-617.
Directors
- Anthony Rosenberg NEC (68)
- Nadim Ahmed PRE (53)
- Patrick Baeuerle CFD (63)
- Jeff Trigilio CFO (37)
- Leigh Zawel CSO (55)
- Raymond Keane OTH (62)
- Jennifer Michaelson OTH (54)
- Corinne Savill OTH (62)
- Thomas Ebeling IND (62)
- Ansbert Gadicke IND (63)
- Stephen Webster IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 15th, 2016
- Public Since
- January 8th, 2021
- No. of Shareholders
- 15
- No. of Employees
- 85
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 43,065,645
- Address
- One Main Street, Suite 1350, CAMBRIDGE, 02142
- Web
- https://www.cullinanoncology.com/
- Phone
- +1 6174104650
- Auditors
- KPMG LLP
Upcoming Events for CGEM
Cullinan Oncology Inc Annual Shareholders Meeting
Q2 2024 Cullinan Oncology Inc Earnings Release
Similar to CGEM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:06 UTC, shares in Cullinan Oncology are trading at $16.58. This share price information is delayed by 15 minutes.
Shares in Cullinan Oncology last closed at $16.58 and the price had moved by +57.01% over the past 365 days. In terms of relative price strength the Cullinan Oncology share price has outperformed the S&P500 Index by +19.12% over the past year.
The overall consensus recommendation for Cullinan Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Cullinan Oncology does not currently pay a dividend.
Cullinan Oncology does not currently pay a dividend.
Cullinan Oncology does not currently pay a dividend.
To buy shares in Cullinan Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $16.58, shares in Cullinan Oncology had a market capitalisation of $714.03m.
Here are the trading details for Cullinan Oncology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CGEM
Based on an overall assessment of its quality, value and momentum Cullinan Oncology is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cullinan Oncology is $25.50. That is 53.8% above the last closing price of $16.58.
Analysts covering Cullinan Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$3.74 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cullinan Oncology. Over the past six months, its share price has outperformed the S&P500 Index by +44.78%.
As of the last closing price of $16.58, shares in Cullinan Oncology were trading +44.38% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cullinan Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $16.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cullinan Oncology's management team is headed by:
- Anthony Rosenberg - NEC
- Nadim Ahmed - PRE
- Patrick Baeuerle - CFD
- Jeff Trigilio - CFO
- Leigh Zawel - CSO
- Raymond Keane - OTH
- Jennifer Michaelson - OTH
- Corinne Savill - OTH
- Thomas Ebeling - IND
- Ansbert Gadicke - IND
- Stephen Webster - IND